Our findings establish a novel therapeutic modality targeting translational control via mRNA relocalization, with enhanced efficacy against cancer cell lines exhibiting high dependency on an RNA-binding protein which regulates MYC mRNA translation, RBM42 [8]. The gene discussed is MYC; the disease is cancer.